Benign Prostatic Hyperplasia Treatment Market
1 Introduction to Research & Analysis Reports
1.1 Benign Prostatic Hyperplasia Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Benign Prostatic Hyperplasia Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Benign Prostatic Hyperplasia Treatment Overall Market Size
2.1 Global Benign Prostatic Hyperplasia Treatment Market Size: 2021 VS 2028
2.2 Global Benign Prostatic Hyperplasia Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Benign Prostatic Hyperplasia Treatment Players in Global Market
3.2 Top Global Benign Prostatic Hyperplasia Treatment Companies Ranked by Revenue
3.3 Global Benign Prostatic Hyperplasia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Benign Prostatic Hyperplasia Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Benign Prostatic Hyperplasia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Benign Prostatic Hyperplasia Treatment Players in Global Market
3.6.1 List of Global Tier 1 Benign Prostatic Hyperplasia Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Benign Prostatic Hyperplasia Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Benign Prostatic Hyperplasia Treatment Market Size Markets, 2021 & 2028
4.1.2 Drug Class
4.1.3 Minimally Invasive Surgeries
4.1.4 Laser Therapy
4.1.5 Others
4.2 By Type - Global Benign Prostatic Hyperplasia Treatment Revenue & Forecasts
4.2.1 By Type - Global Benign Prostatic Hyperplasia Treatment Revenue, 2017-2022
4.2.2 By Type - Global Benign Prostatic Hyperplasia Treatment Revenue, 2023-2028
4.2.3 By Type - Global Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Benign Prostatic Hyperplasia Treatment Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Specialty Clinics
5.1.5 Others
5.2 By Application - Global Benign Prostatic Hyperplasia Treatment Revenue & Forecasts
5.2.1 By Application - Global Benign Prostatic Hyperplasia Treatment Revenue, 2017-2022
5.2.2 By Application - Global Benign Prostatic Hyperplasia Treatment Revenue, 2023-2028
5.2.3 By Application - Global Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Benign Prostatic Hyperplasia Treatment Market Size, 2021 & 2028
6.2 By Region - Global Benign Prostatic Hyperplasia Treatment Revenue & Forecasts
6.2.1 By Region - Global Benign Prostatic Hyperplasia Treatment Revenue, 2017-2022
6.2.2 By Region - Global Benign Prostatic Hyperplasia Treatment Revenue, 2023-2028
6.2.3 By Region - Global Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Benign Prostatic Hyperplasia Treatment Revenue, 2017-2028
6.3.2 US Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.3.3 Canada Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.3.4 Mexico Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Benign Prostatic Hyperplasia Treatment Revenue, 2017-2028
6.4.2 Germany Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4.3 France Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4.4 U.K. Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4.5 Italy Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4.6 Russia Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.4.8 Benelux Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Benign Prostatic Hyperplasia Treatment Revenue, 2017-2028
6.5.2 China Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.5.3 Japan Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.5.4 South Korea Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.5.6 India Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Benign Prostatic Hyperplasia Treatment Revenue, 2017-2028
6.6.2 Brazil Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.6.3 Argentina Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue, 2017-2028
6.7.2 Turkey Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.7.3 Israel Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
6.7.5 UAE Benign Prostatic Hyperplasia Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Abbott
7.1.1 Abbott Corporate Summary
7.1.2 Abbott Business Overview
7.1.3 Abbott Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.1.4 Abbott Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.1.5 Abbott Key News
7.2 Allergan plc
7.2.1 Allergan plc Corporate Summary
7.2.2 Allergan plc Business Overview
7.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.2.4 Allergan plc Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.2.5 Allergan plc Key News
7.3 Astellas Pharma
7.3.1 Astellas Pharma Corporate Summary
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.3.4 Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.3.5 Astellas Pharma Key News
7.4 Asahi Kasei Corporation
7.4.1 Asahi Kasei Corporation Corporate Summary
7.4.2 Asahi Kasei Corporation Business Overview
7.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.4.4 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.4.5 Asahi Kasei Corporation Key News
7.5 Boehringer Ingelheim GmbH
7.5.1 Boehringer Ingelheim GmbH Corporate Summary
7.5.2 Boehringer Ingelheim GmbH Business Overview
7.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.5.4 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.5.5 Boehringer Ingelheim GmbH Key News
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Corporate Summary
7.6.2 GlaxoSmithKline Business Overview
7.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.6.4 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.6.5 GlaxoSmithKline Key News
7.7 Pfizer
7.7.1 Pfizer Corporate Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.7.4 Pfizer Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.7.5 Pfizer Key News
7.8 Sanofi
7.8.1 Sanofi Corporate Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.8.4 Sanofi Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.8.5 Sanofi Key News
7.9 Teva Pharmaceutical Industries
7.9.1 Teva Pharmaceutical Industries Corporate Summary
7.9.2 Teva Pharmaceutical Industries Business Overview
7.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.9.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.9.5 Teva Pharmaceutical Industries Key News
7.10 Merck
7.10.1 Merck Corporate Summary
7.10.2 Merck Business Overview
7.10.3 Merck Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.10.4 Merck Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.10.5 Merck Key News
7.11 Boston Scientific Corporation
7.11.1 Boston Scientific Corporation Corporate Summary
7.11.2 Boston Scientific Corporation Business Overview
7.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.11.4 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.11.5 Boston Scientific Corporation Key News
7.12 Teleflex Incorporated
7.12.1 Teleflex Incorporated Corporate Summary
7.12.2 Teleflex Incorporated Business Overview
7.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.12.4 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.12.5 Teleflex Incorporated Key News
7.13 Endo International
7.13.1 Endo International Corporate Summary
7.13.2 Endo International Business Overview
7.13.3 Endo International Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.13.4 Endo International Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.13.5 Endo International Key News
7.14 Urologix
7.14.1 Urologix Corporate Summary
7.14.2 Urologix Business Overview
7.14.3 Urologix Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.14.4 Urologix Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.14.5 Urologix Key News
7.15 LISA Laser
7.15.1 LISA Laser Corporate Summary
7.15.2 LISA Laser Business Overview
7.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.15.4 LISA Laser Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.15.5 LISA Laser Key News
7.16 Olympus
7.16.1 Olympus Corporate Summary
7.16.2 Olympus Business Overview
7.16.3 Olympus Benign Prostatic Hyperplasia Treatment Major Product Offerings
7.16.4 Olympus Benign Prostatic Hyperplasia Treatment Revenue in Global Market (2017-2022)
7.16.5 Olympus Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Benign Prostatic Hyperplasia Treatment Market Opportunities & Trends in Global Market
Table 2. Benign Prostatic Hyperplasia Treatment Market Drivers in Global Market
Table 3. Benign Prostatic Hyperplasia Treatment Market Restraints in Global Market
Table 4. Key Players of Benign Prostatic Hyperplasia Treatment in Global Market
Table 5. Top Benign Prostatic Hyperplasia Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Benign Prostatic Hyperplasia Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Benign Prostatic Hyperplasia Treatment Product Type
Table 9. List of Global Tier 1 Benign Prostatic Hyperplasia Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Benign Prostatic Hyperplasia Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Benign Prostatic Hyperplasia Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Benign Prostatic Hyperplasia Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Benign Prostatic Hyperplasia Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Benign Prostatic Hyperplasia Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Abbott Corporate Summary
Table 31. Abbott Benign Prostatic Hyperplasia Treatment Product Offerings
Table 32. Abbott Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Allergan plc Corporate Summary
Table 34. Allergan plc Benign Prostatic Hyperplasia Treatment Product Offerings
Table 35. Allergan plc Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Astellas Pharma Corporate Summary
Table 37. Astellas Pharma Benign Prostatic Hyperplasia Treatment Product Offerings
Table 38. Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Asahi Kasei Corporation Corporate Summary
Table 40. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product Offerings
Table 41. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Boehringer Ingelheim GmbH Corporate Summary
Table 43. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product Offerings
Table 44. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 45. GlaxoSmithKline Corporate Summary
Table 46. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product Offerings
Table 47. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Pfizer Corporate Summary
Table 49. Pfizer Benign Prostatic Hyperplasia Treatment Product Offerings
Table 50. Pfizer Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Sanofi Corporate Summary
Table 52. Sanofi Benign Prostatic Hyperplasia Treatment Product Offerings
Table 53. Sanofi Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Teva Pharmaceutical Industries Corporate Summary
Table 55. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product Offerings
Table 56. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Merck Corporate Summary
Table 58. Merck Benign Prostatic Hyperplasia Treatment Product Offerings
Table 59. Merck Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Boston Scientific Corporation Corporate Summary
Table 61. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product Offerings
Table 62. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Teleflex Incorporated Corporate Summary
Table 64. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product Offerings
Table 65. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Endo International Corporate Summary
Table 67. Endo International Benign Prostatic Hyperplasia Treatment Product Offerings
Table 68. Endo International Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Urologix Corporate Summary
Table 70. Urologix Benign Prostatic Hyperplasia Treatment Product Offerings
Table 71. Urologix Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 72. LISA Laser Corporate Summary
Table 73. LISA Laser Benign Prostatic Hyperplasia Treatment Product Offerings
Table 74. LISA Laser Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
Table 75. Olympus Corporate Summary
Table 76. Olympus Benign Prostatic Hyperplasia Treatment Product Offerings
Table 77. Olympus Benign Prostatic Hyperplasia Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Benign Prostatic Hyperplasia Treatment Segment by Type in 2021
Figure 2. Benign Prostatic Hyperplasia Treatment Segment by Application in 2021
Figure 3. Global Benign Prostatic Hyperplasia Treatment Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Benign Prostatic Hyperplasia Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Benign Prostatic Hyperplasia Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue in 2021
Figure 8. By Type - Global Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 12. US Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 24. China Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Benign Prostatic Hyperplasia Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Abbott Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Allergan plc Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Pfizer Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sanofi Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Merck Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Endo International Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Urologix Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. LISA Laser Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Olympus Benign Prostatic Hyperplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Industry Market Size
